Why isn’t gene therapy available to more patients? Blame millionaire prices and uncertainty as to its effectiveness
By Oriol Güell,
El País
| 07. 07. 2024
Image by Nick Youngson from Pix4free
Darius is 15 years old and is a dazzling example of how medical research has advanced. Born with a rare and lethal genetic disease, early active cerebral adrenoleukodystrophy — CALD, the same condition that killed his older brother Danuk — the adolescent boy is today, healthy and happy in his hometown of Quintanar de la Orden, in the Spanish province of Toledo. His recovery has been thanks to a gene therapy called Skysona. A benevolent virus, a Trojan horse that was introduced into his body when the boy was five years old, it was able to replace the boy’s defective gene with a healthy one, thus saving his life.
But to the frustration of his doctors and other families, Darius’s treatment has not been available on the European market since 2021, due to a decision made by its pharmaceutical company Bluebird Bio that has left dozens of young people in the EU without the opportunity to follow Darius down the same path to survival. “It is difficult to comprehend,” says Carmen Sever, president...
Related Articles
GeneWatch UK has prepared a briefing on the genetic modification of nature for the International Union for Conservation of Nature (IUCN) Congress in October 2025
The upcoming Congress claims to be “where the world comes together to set priorities and drive conservation and sustainable development action.” A major concern for those on the outside is that the Congress may advance plans to develop and encourage the use of synthetic biology in nature conservation. This could at first glance sound like...
By Aaron Ginn, The Washington Post | 09.12.2025
Earlier this year, I had dinner in D.C. with Jensen Huang, the president and chief executive of Nvidia. At one point, he said something that struck me: “Why is everyone here so negative?”
He wasn’t referring to the economy...
By Roni Caryn Rabin, The New York Times | 08.25.2025
Scientists have dreamed for centuries about using animal organs to treat ailing humans. In recent years, those efforts have begun to bear fruit: Researchers have begun transplanting the hearts and kidneys of genetically modified pigs into patients, with varying degrees...
The Center for Genetics and Society is delighted to recommend the current edition of GMWatch Review – Number 589. UK-based GMWatch, a long-standing ally, was founded in 1998 by Jonathan Matthews as an independent organization seeking to counter the enormous corporate political power and propaganda of the GMO industry and its supporters. Matthews and Claire Robinson are its directors and managing editors.
CGS works to ensure that social justice, equity, human rights, and democratic governance are front...